KRAS and colorectal carcinoma: Furthermore, emerging studies indicate that molecular subtypes of CRC (e.g., adenomatous polyposis coli (APC)-mutated, Kirsten rat sarcoma virus (KRAS)-mutant, or Mothers against decapentaplegic homolog 4 (SMAD4)-deficient tumors) may respond differently to statin therapy, highlighting the potential for precision chemoprevention approaches [7, 8].